X
Pharma Advancement
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

    AstraZeneca Eyes Acquisition To Develop Cell Therapies

    Advanced Instruments All Set To Merge With Nova Biomedical

    Taiho Pharmaceutical Buys Araris Biotech AG For $740 Million

    Oracle Wins the Asia Pacific Biopharma Excellence Awards

    Continuous Manufacturing is Improving Biopharma Production

    AI in Drug Commercialization Market to Grow CAGR 24% by 2032

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

    AstraZeneca Eyes Acquisition To Develop Cell Therapies

    Advanced Instruments All Set To Merge With Nova Biomedical

    Taiho Pharmaceutical Buys Araris Biotech AG For $740 Million

    Oracle Wins the Asia Pacific Biopharma Excellence Awards

    Continuous Manufacturing is Improving Biopharma Production

    AI in Drug Commercialization Market to Grow CAGR 24% by 2032

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Drug Development Clinical Trials

CSL Behring begins pediatric Phase III hemophilia B study of rIX-FP

Yuvraj_pawp by Yuvraj_pawp
22nd February 2013
in Clinical Trials, Drug Development

CSL Behring has commenced the patient enrollment in pivotal pediatric Phase III hemophilia B study of recombinant fusion protein linking coagulation factor IX with recombinant albumin (rIX-FP).

The study is designed to assess rIX-FP’s safety, efficacy and pharmacokinetic profile in children who previously received treatment.

CSL Behring along with its parent company, CSL Limited, is developing rIX-FP by means of the PROLONG-9FP clinical trial program.

The program aims at prevention and treatment of bleeding events in patients with factor IX deficiency.

CSL Limited chief scientist Dr. Andrew Cutherbertson said the company is advancing the recombinant coagulation factor development program.

“The long history of profound expertise and commitment CSL brings to developing safe and effective therapies to improve the lives of those affected by rare and serious bleeding disorders remains the key to our ongoing success in this therapeutic area,” Cutherbertson added.

rIX-FP established positive results in the phase I study, conducted in hemophilia B patients, demonstrating an extension in half-life of 5.3 times compared to existing recombinant FIX therapy.

According to the study data concerning the tissue distribution, rIX-FP was detectable significantly longer than the study comparator product in the tissues such as the bone.

CSL Behring research and development vice president Dr. Stefan Schulte said, “These results provide further evidence that rIX-FP is an extended half-life recombinant factor IX with the potential to reduce the number of injections needed in patients receiving prophylaxis from two or three injections per week with the study comparator product,to once weekly or significantly less frequently with rIX-FP.”

Previous Post

GlycoMimetics completes enrollment in Phase 2 study of GMI-1070

Next Post

Boston Therapeutics presents PAZ320 drug positive Phase ll results

Related Posts

Clinical Development
Articles

AI Revolutionizing Drug Discovery and Clinical Development

19th April 2025
Drug-Development
Articles

China’s Super Me-Too Drug Development: A New Pharma Frontier

18th April 2025
Omics Based Clinical Trials
Asia

Asia Pacific Omics-Based Clinical Trials Market Growth

16th April 2025
Insights

AstraZeneca Eyes Acquisition To Develop Cell Therapies

24th March 2025
Drug Development

Advanced Instruments All Set To Merge With Nova Biomedical

22nd March 2025
Drug Development

Taiho Pharmaceutical Buys Araris Biotech AG For $740 Million

21st March 2025
Next Post

Avaxia treats first patient in ulcerative colitis drug study

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In